How to buy Chiasma (CHMA) stock

Chiasma, Inc is a biotechnology business based in the US. Chiasma shares (CHMA) are listed on the NASDAQ and all prices are listed in US Dollars. Chiasma employs 84 staff and has a trailing 12-month revenue of around 0.00.

Chiasma stock price (NASDAQ: CHMA)

Use our graph to track the performance of CHMA stocks over time.

Chiasma shares at a glance

• Key figures

Information last updated 2021-07-22.

Latest market close	$4.23
52-week range	$2.77 - $5.74
50-day moving average	$4.36
200-day moving average	$3.87
Wall St. target price	$9.10
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.23

Buy Chiasma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Chiasma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Chiasma, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Chiasma price performance over time

Historical closes compared with the close of $4.23 from 2021-05-28

1 week (2021-07-17)	N/A
1 month (2021-06-28)	-10.19%
3 months (2021-04-28)	36.89%
6 months (2021-01-24)	N/A

1 year (2020-07-24)	N/A
2 years (2019-07-24)	N/A
3 years (2018-07-24)	N/A
5 years (2016-07-24)	N/A

Chiasma financials

Revenue TTM	$3 million
Gross profit TTM	$1 million
Return on assets TTM	-37.05%
Return on equity TTM	-133.81%
Profit margin	0%
Book value	$1.08
Market capitalisation	$272.6 million

TTM: trailing 12 months

Shorting Chiasma shares

There are currently 849,920 Chiasma shares held short by investors – that's known as Chiasma's "short interest". This figure is 67.4% down from 2.6 million last month.

There are a few different ways that this level of interest in shorting Chiasma shares can be evaluated.

Chiasma's "short interest ratio" (SIR)

Chiasma's "short interest ratio" (SIR) is the quantity of Chiasma shares currently shorted divided by the average quantity of Chiasma shares traded daily (recently around 1.3 million). Chiasma's SIR currently stands at 0.63. In other words for every 100,000 Chiasma shares traded daily on the market, roughly 630 shares are currently held short.

However Chiasma's short interest can also be evaluated against the total number of Chiasma shares, or, against the total number of tradable Chiasma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Chiasma's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Chiasma shares in existence, roughly 10 shares are currently held short) or 0.0256% of the tradable shares (for every 100,000 tradable Chiasma shares, roughly 26 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Chiasma.

Find out more about how you can short Chiasma stock.

Chiasma share dividends

We're not expecting Chiasma to pay a dividend over the next 12 months.

Chiasma share price volatility

Over the last 12 months, Chiasma's shares have ranged in value from as little as $2.77 up to $5.74. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Chiasma's is 1.2552. This would suggest that Chiasma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Chiasma overview

Chiasma, Inc. , a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts. .

Frequently asked questions

What percentage of Chiasma is owned by insiders or institutions?
Currently 0.581% of Chiasma shares are held by insiders and 76.624% by institutions. How many people work for Chiasma?
Latest data suggests 84 work at Chiasma. When does the fiscal year end for Chiasma?
Chiasma's fiscal year ends in December. Where is Chiasma based?
Chiasma's address is: Building C East, Needham, MA, United States, 02494 What is Chiasma's ISIN number?
Chiasma's international securities identification number is: US16706W1027 What is Chiasma's CUSIP number?
Chiasma's Committee on Uniform Securities Identification Procedures number is: 16706W102